Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma

International Journal of Pharmaceutics

Volumn 453, Issue 2, 2013, Pages 498-505

  Zhang, Xiaoyan ^a   Chen, Jun ^a   Kang, Yu ^a   Hong, Shanshan ^a   Zheng, Yufang ^b   Sun, Hong ^a   Xu, Congjian ^a,c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Follicle stimulating hormone; Nanoparticle; Ovarian carcinoma; Paclitaxel; Targeted therapy

Indexed keywords

FOLLITROPIN BETA[81-95] PEPTIDE; FOLLITROPIN DERIVATIVE; FOLLITROPIN RECEPTOR; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN MODIFICATION; TUMOR XENOGRAFT; WEIGHT REDUCTION; X RAY PHOTOELECTRON SPECTROSCOPY; ZETA POTENTIAL;

EID: 84884132357     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.038     Document Type: Article

References (55)

1. Al-Timimi, A., Buckley, C.H., Fox, H., 1986. An immunohistochemical study of the incidence and significance of human gonadotrophin and prolactin binding sites in normal and neoplastic human ovarian tissue. Br. J. Cancer 53, 321-329. (Pubitemid 16133101)
2. Bast, R.J., Hennessy, B., Mills, G.B., 2009. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 9, 415-428.
3. Beck, E.P., Vincenti, D., Licht, P., Berkholz, A., Jager, W., Lang, N., Merkle, E., 2000. In vitro activity of human chorionic gonadotropin (hCG) - doxorubicin conjugates against ovarian cancer cells. Anticancer. Res. 20, 3001-3006.
4. Ben-Josef, E., Yang, S.Y., Ji, T.H., Bidart, J.M., Garde, S.V., Chopra, D.P., Porter, A.T., Tang, D.G., 1999. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J. Urol. 161, 970-976. (Pubitemid 29422418)
5. Bodek, G., Vierre, S., Rivero-Muller, A., Huhtaniemi, I., Ziecik, A.J., Rahman, N.A., 2005. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia 7, 497-508. (Pubitemid 40791868)
6. Dharap, S.S., Wang, Y., Chandna, P., Khandare, J.J., Qiu, B., Gunaseelan, S., Sinko, P.J., Stein, S., Farmanfarmaian, A., Minko, T., 2005. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. U.S.A. 102, 12962-12967. (Pubitemid 41279472)
7. Emons, G., Kaufmann, M., Gorchev, G., Tsekova, V., Grundker, C., Gunthert, A.R., Hanker, L.C., Velikova, M., Sindermann, H., Engel, J., Schally, A.V., 2010. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol. Oncol. 119, 457-461.
8. Emons, G., Pahwa, G.S., Brack, C., Sturm, R., Oberheuser, F., Knuppen, R., 1989. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur. J. Cancer Clin. Oncol. 25, 215-221. (Pubitemid 19054823)
9. Emons, G., Sindermann, H., Engel, J., Schally, A.V., Grundker, C., 2009. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 90, 15-18.
10. Engel, J.B., Schally, A.V., Buchholz, S., Seitz, S., Emons, G., Ortmann, O., 2012. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch. Gynecol. Obstet. 286, 437-442.
11. Fung-Kee-Fung, M., Oliver, T., Elit, L., Oza, A., Hirte, H.W., Bryson, P., 2007. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol. 14, 195-208.
12. Grasso, P., Santa-Coloma, T.A., Reichert Jr., L.E., 1991. Synthetic peptides corresponding to human follicle-stimulating hormone (hFSH)-beta-(1-15) and hFSH-beta-(51-65) induce uptake of 45Ca++ by liposomes: evidence for calcium-conducting transmembrane channel formation. Endocrinology 128, 2745-2751.
13. Grundker, C., Gunthert, A.R., Westphalen, S., Emons, G., 2002. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur. J. Endocrinol. 146, 1-14. (Pubitemid 34126412)
14. Jankowska, A., Andrusiewicz, M., Grabowski, J., Nowak-Markwitz, E., Warchol, J.B., 2008. Coexpression of human chorionic gonadotropin beta subunit and its receptor in nontrophoblastic gynecological cancer. Int. J. Gynecol. Cancer 18, 1102-1107.
15. Jankowska, A.G., Andrusiewicz, M., Fischer, N., Warchol, P.J., 2010. Expression of hCG and GnRHs and their receptors in endometrial carcinoma and hyperplasia. Int. J. Gynecol. Cancer 20, 92-101.
16. Landen Jr., C.N., Birrer, M.J., Sood, A.K., 2008. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 26, 995-1005. (Pubitemid 351398093)
17. Kammerman, S., Demopoulos, R.I., Raphael, C., Ross, J., 1981. Gonadotropic hormone binding to human ovarian tumors. Hum. Pathol. 12, 886-890. (Pubitemid 12227616)
18. Kim, S.H., Jeong, J.H., Lee, S.H., Kim, S.W., Park, T.G., 2008. LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug. Chem. 19, 2156-2162.
19. Konishi, I., 2006. Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int. J. Gynecol. Cancer 16, 16-22.
20. La Marca, A., Carducci, A.A., Stabile, G., Rivasi, F., Volpe, A., 2005. Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium. Gynecol. Endocrinol. 21, 303-306. (Pubitemid 43068026)
21. Ledermann, J.A., Raja, F.A., 2010. Targeted trials in ovarian cancer. Gynecol. Oncol. 119, 151-156.
22. Lutz, A.M., Willmann, J.K., Drescher, C.W., Ray, P., Cochran, F.V., Urban, N., Gambhir, S.S., 2011. Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology 259, 329-345.
23. Markman, M., 2008. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol. Sci. 29, 515-519.
24. Mertens-Walker, I., Baxter, R.C., Marsh, D.J., 2012. Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett. 324, 152-159.
25. Mezo, G., Manea, M., 2010. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin. Drug Deliv. 7, 79-96.
26. Minegishi, T., Kameda, T., Hirakawa, T., Abe, K., Tano, M., Ibuki, Y., 2000. Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin. Cancer Res. 6, 2764-2770. (Pubitemid 30482116)
27. Morbeck, D.E., Roche, P.C., Keutmann, H.T., McCormick, D.J., 1993. A receptor binding site identified in the region 81-95 of the beta-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (hCG). Mol. Cell. Endocrinol. 97, 173-181. (Pubitemid 23328185)
28. Nagy, A., Schally, A.V., 2005. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol. Reprod. 73, 851-859. (Pubitemid 41507486)
29. Nagy, A., Schally, A.V., Armatis, P., Szepeshazi, K., Halmos, G., Kovacs, M., Zarandi, M., Groot, K., Miyazaki, M., Jungwirth, A., Horvath, J., 1996. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. U.S.A. 93, 7269-7273. (Pubitemid 26243538)
30. Nakano, R., Kitayama, S., Yamoto, M., Shima, K., Ooshima, A., 1989. Localization of gonadotropin binding sites in human ovarian neoplasms. Am. J. Obstet. Gynecol. 161, 905-910. (Pubitemid 19266197)
31. Parrott, J.A., Doraiswamy, V., Kim, G., Mosher, R., Skinner, M.K., 2001. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol. Cell. Endocrinol. 172, 213-222. (Pubitemid 32098413)
32. Passarella, R.J., Spratt, D.E., van der Ende, A.E., Phillips, J.G., Wu, H., Sathiyakumar, V., Zhou, L., Hallahan, D.E., Harth, E., Diaz, R., 2010. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res. 70, 4550-4559.
33. Radu, A., Pichon, C., Camparo, P., Antoine, M., Allory, Y., Couvelard, A., Fromont, G., Hai, M.T., Ghinea, N., 2010. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N. Engl. J. Med. 363, 1621-1630.
34. Rahimipour, S., Ben-Aroya, N., Ziv, K., Chen, A., Fridkin, M., Koch, Y., 2003. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J. Med. Chem. 46, 3965-3974. (Pubitemid 37122443)
35. Reubi, J.C., 2003. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24, 389-427. (Pubitemid 37056239)
36. Santa Coloma, T.A., Dattatreyamurty, B., Reichert Jr., L.E., 1990. A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH. Biochemistry-US 29, 1194-1200. (Pubitemid 20053842)
37. Santa Coloma, T.A., Reichert Jr., L.E., 1990. Identification of a follicle-stimulating hormone receptor-binding region in hFSH-beta-(81-95) using synthetic peptides. J. Biol. Chem. 265, 5037-5042. (Pubitemid 20117147)
38. Schally, A.V., 2008. New approaches to the therapy of various tumors based on peptide analogues. Horm. Metab. Res. 40, 315-322. (Pubitemid 351859442)
39. Schally, A.V., Nagy, A., 1999. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 141, 1-14. (Pubitemid 29370830)
40. Schmidt, M.M., Wittrup, K.D., 2009. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 8, 2861-2871.
41. Srkalovic, G., Schally, A.V., Wittliff, J.L., Day Jr., T.G., Jenison, E.L., 1998. Presence and characteristics of receptors for [d-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int. J. Oncol. 12, 489-498. (Pubitemid 28097966)
42. Taratula, O., Garbuzenko, O.B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V.P., He, H., Minko, T., 2009. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release 140, 284-293.
43. Ulloa-Aguirre, A., Timossi, C., 1998. Structure-function relationship of follicle-stimulating hormone and its receptor. Hum. Reprod. Update 4, 260-283. (Pubitemid 28422906)
44. Volker, P., Grundker, C., Schmidt, O., Schulz, K.D., Emons, G., 2002. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am. J. Obstet. Gynecol. 186, 171-179. (Pubitemid 34165428)
45. Wang, J., Lin, L., Parkash, V., Schwartz, P.E., Lauchlan, S.C., Zheng, W., 2003. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int. J. Cancer 103, 328-334. (Pubitemid 36076425)
46. Westphalen, S., Kotulla, G., Kaiser, F., Krauss, W., Werning, G., Elsasser, H.P., Nagy, A., Schulz, K.D., Grundker, C., Schally, A.V., Emons, G., 2000. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int. J. Oncol. 17, 1063-1069.
47. Xiangbing, H., Yankai, Z., Ming, L., Yong, L., Yu, Z., Huiyong, Z., Yingying, C., Jing, H., Yun, X., Liang, J., Rongyue, C., Jingjing, L., 2010. The fusion protein of HSP65 with tandem repeats of beta-hCG acting as a potent tumor vaccine in suppressing hepatocarcinoma. Int. Immunopharmacol. 10, 230-238.
48. Xiao, K., Li, Y., Lee, J.S., Gonik, A.M., Dong, T., Fung, G., Sanchez, E., Xing, L., Cheng, H.R., Luo, J., Lam, K.S., 2012. OA02 peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 72, 2100-2110.
49. Yang, W.H., Wieczorck, M., Allen, M.C., Nett, T.M., 2003. Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors. Endocrinology 144, 1456-1463. (Pubitemid 36428487)
50. Zhang, X., Xu, C., 2011. Application of reproductive hormone peptides for tumor targeting. Curr. Pharm. Biotechnol. 12, 1144-1152.
51. Zhang, X.Y., Chen, J., Gao, X.L., Sun, H., Xu, C.J., 2008. Preparation and in vitro targeting of follicle stimulating hormone polypeptide modified nanoparticles. Zhonghua Fu Chan Ke Za Zhi 43, 533-537.
52. Zhang, X.Y., Chen, J., Zheng, Y.F., Gao, X.L., Kang, Y., Liu, J.C., Cheng, M.J., Sun, H., Xu, C.J., 2009. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res. 69, 6506-6514.
53. Zheng, W., Lu, J.J., Luo, F., Zheng, Y., Feng, Y., Felix, J.C., Lauchlan, S.C., Pike, M.C., 2000. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol. Oncol. 76, 80-88. (Pubitemid 30048324)
54. Zheng, W., Magid, M.S., Kramer, E.E., Chen, Y.T., 1996. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am. J. Pathol. 148, 47-53. (Pubitemid 26019642)
55. Ziebarth, A.J., Landen, C.J., Alvarez, R.D., 2012. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clin. Obstet. Gynecol. 55, 156-172.